TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06028932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan will be administered at 10 mg/kg weekly as an infusion for 2 consecutive weeks (2 weekly doses plus 1 week without treatment represents a single 3 week cycle). Treatment can be continued without a rest period in the absence of progression of disease or unacceptable toxicity.
Study: NCT06631300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: A prednisone taper will be given to the subjects as follows: prednisone 40mg for 3 days, prednisone 30mg for 3 days, prednisone 20mg for 3 days, prednisone 10mg for 3 days, prednisone 5mg for 3 days, then off for a total of 15 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo taper will be given to match the same number of pills administered in each stage of the prednisone taper.
Study: NCT06629415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: injecting 7.5 mg (3 ml of a 25 mg/10 ml solution) intravenously in the pre-operative holding area at least 20 minutes before surgery.~Before dissecting the adhesions surrounding the hepatoduodenal ligament, fluorescence cholangiography (FC) is carried out to determine the anatomy of the extrahepatic bile ducts by converting the full-color images to fluorescence images using filter switches on the camera head and/or light source in the laparoscopic imaging system (Fig. 1). The \&amp;#34;critical view of safety\&amp;#34; is then reached by dissecting Calot\&amp;#39;s triangle and using FC to verify whether the accessory bile ducts are present or absent throughout the procedures. It is necessary to acquire fluorescence image

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Drug
Description: 1.25 mg of ICG powder was dissolved in 3 cm of saline, and the concentration was roughly 0.04 mg after each 1 cm of saline was diluted by 9 cm of saline. In order to prevent dye leakage that might result in false FC results, a veress needle was inserted through the abdominal wall and into the gall bladder fundus through the liver bed. The puncture site was then cauterized.
Study: NCT06158958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-303
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-303
Description: Intravenous (IV) Infusion
Study: NCT06237855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-drain removal
Description: Subjects will be trained to self-remove drain at home following ventral hernia repair.
Study: NCT06298708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mevac-A vaccine
Description: Mevac-A: A freeze-dried live-attenuated hepatitis A vaccine.~Dose and administration: a freeze-dried live-attenuated vaccine, subcutaneous injection of 0.5 ml will be administered for 1 time.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix 720 Junior
Description: Havrix 720 Junior: An inactivated hepatitis A vaccine, 720 ELISA units per 0.5 ml of formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain).~Dose and administration: a pre-filled syringe, intramuscular injection of 0.5 ml will be administered for 2 times with 6-month interval.
Study: NCT06268847

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product.~2 capsules per day for 90 days of placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACT01
Description: 2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACT02
Description: 2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product.
Study: NCT06158958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-303
Description: Intravenous (IV) Infusion
Study: NCT04012073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weaning from mechanical ventilation
Description: A 30-120-minute spontaneous breathing trial will be initiated as the following criteria are met and whether the patient tolerates fully assist ventilation with PEEP≤8 cmH2O for at least 4 hours without experiencing hypoxemia (SpO2\<88% or PaO2/FiO2\<150mmHg):~* improvement or resolution of the underlying cause of acute respiratory failure~* normal sensorium~* correction of arterial hypoxemia (PaO2 ≥ 60 mmHg at a FiO2 ≤ 0.4 with PEEP ≤ 8 cmH2O);~* absence of fever (≥ 38 °C) or sepsis;~* blood hemoglobin concentration of 7 g/dL or more;~* hemodynamic stability~For the purpose of the study, success of the spontaneous breathing trial will be defined as presence of the following criteria:~* respiratory rate \< 35/min,~* arterial oxygen saturation ≥ 90%,~* heart rate \< 120/min,~* systolic blood pressure \> 90 and \< 160 mmHg~* adequate cough. If the spontaneous breathing trial is successful, the patient will be extubated.
Study: NCT04830410

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructan reintroduction
Description: Patients will reintroduce fructan powder after 14-day of a low FODMAP diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo reintroduction
Description: Patients will reintroduce placebo powder after 14-day of a low FODMAP diet
Study: NCT05887908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-administration of cefepime and nacubactam
Description: 2 g cefepime and 1 g nacubactam
Study: NCT04012073

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation
Description: Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%\>SpO2\>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician.
Study: NCT05887908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co-administration of aztreonam and nacubactam
Description: 2 g aztreonama and 1 g nacubactam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem/cilastatin
Description: 1 g imipenem/1 g cilastatin
Study: NCT05943678

Intervention type: DEVICE
Intervention: Siemens Magnetom 7T Plus
Description: Magnetic Resonance Spectroscopy
Study: NCT04012073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation
Description: Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%\>SpO2\>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician.
Study: NCT05943678

Intervention type: DEVICE
Intervention: Siemens Magnetom 7T Plus
Description: Magnetic Resonance Spectroscopy

Intervention type: DEVICE
Intervention: Siemens Magnetom 7T Plus
Description: Magnetic Resonance Spectroscopy
Study: NCT05503277

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LTSD
Description: measuring seal pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: measuring seal pressure
Study: NCT06209619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT05586776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% Chlorhexidine Gluconate
Description: Used for daily showering/bathing for 30 days after hospital discharge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Mupirocin
Description: Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Soap Without Antiseptic Properties (Placebo)
Description: Used for daily showering/bathing for 30 days after hospital discharge.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Ointment
Description: Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
Study: NCT05352282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: SAPB will be done preoperative before induction of anesthesia under songraphic guidance and aseptic conditions with the patient in the lateral position, with the side of the surgical side up and the upper limb hanging over the patient's head. The ribs will be then counted, and when the 5th rib is identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane. The ribs, pleura, overlying serratus muscle and latissimus dorsi muscle will be identified, and the needle will be advanced cephalic in-plane until the tip reaches the plane between the serratus anterior and latissimus dorsi. Afterward, 2 mL dextrose 5% will be injected; then, 30 mL of bupivacaine 0.25% will be injected in the plane between the serratus anterior and latissimus dorsi.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Intrathecal Fentanyl Injection
Description: Patients will receive 25 microgram intracthecal fentanyl immediately preoperative.
Study: NCT05144464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: Subjects receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
Study: NCT06384482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNC115 injection
Description: SNC115 Injection is DLL3 CART.
Study: NCT05443919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TwiFlow-Thrombectomy Catheter System
Description: Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'.
Study: NCT02107222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2-Removal (PALP-Device/MaquetCP)
Description: extracorporeal circuit to remove CO2 out of the blood
Study: NCT04775069

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: Intramuscular injection
Study: NCT05699746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: Capecitabine 1000 mg/m2, twice daily PO for 14 days, repeat every 3 weeks, for at most 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 IV day 1, combined with Capecitabine, for at most 8 cycles.
Study: NCT04741542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: This study aims to establish the safety of SP-420 administered orally three times per week (TIW).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-420
Description: This study aims to establish the safety of SP-420 administered orally three times per week (TIW).
Study: NCT06442592

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: An EDTA blood sample will be taken from the children and their two parents. Sample volume will be 2 x 3mL.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: An EDTA blood sample will be taken from the children and their two parents. Sample volume will be 2 x 3mL.
Study: NCT05674240

Intervention type: DEVICE
Intervention: Intrathecal Targeted Drug Delivery
Description: Intrathecal drug delivery systems (IDDs) deliver small doses of analgesics directly to the spinal cord.

Intervention type: COMBINATION_PRODUCT
Intervention: Conservative medical management
Description: Including physical therapy, oral or transdermal medications and injections

Intervention type: COMBINATION_PRODUCT
Intervention: Conservative medical management
Description: Including physical therapy, oral or transdermal medications and injections
Study: NCT05902741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RiSE
Description: RiSE provides participants with a platform to share the emotional impact of race-based stress and to offer supportive listening to their peers. Participants explicitly discuss the experiences they have as African American women, taking into account the ways which the interaction between their racial and gender identities shapes their experiences. Facilitators review difficulties associated with addressing racism and unique experiences of Black women at interpersonal and structural levels, and provide evidence of strategies to promote effective communication and internal emotional regulation regarding experiences of racism. Facilitators provide psychoeducation on intersectionality, structural racism, overt racism, microaggressions, and internalized racism. Following this education, facilitators help participants utilize cognitive-behavioral strategies to understand consequent thoughts, feelings, and actions associated with such experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEP
Description: The HEP group will consist of classes focusing on wellness promotion. Expert speakers provide the HEP classes (e.g dietician, pharmacist).
Study: NCT04987814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HD-sEMG
Description: high definition surface electromyography, allowing the recording of muscle activation signals sensitive to the intensity of the contraction and indirectly to the muscle strength as well as to the muscular fatigability, but also capable of measuring the modifications of the recruitment modalities of the motor units. This recording will be made on the rectus femoris during knee extension, either in the lying position or during chair lifts, depending on the patient's functional state.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: - Quadriceps muscle ultrasound
Description: Muscle Ultrasound with Philips Lumify Wireless Handheld Ultrasound for Android - Model - L12-4 linear probe, allowing performance at the patient's bed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPAQ Physical Activity Questionnaire.
Description: physical activity assessment questionnaire/adapted version for seniors
Study: NCT04925661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC53856
Description: Either dose of HEC53856 will be administered after fasting .
Study: NCT06639646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics supplements
Description: A Dietary intervention group receiving health education message about healthy diet and probiotics supplements ( spores of poly antibiotic resistant Lactobacilli 5 billion in form of capsules registrated by the Egyption drug auyjority EDA and sold in Egyption markets under brand name Lactèol Forte ® capsules by Rameda® company.~The probiotic supplement is recommended to be given twice daily for 12 wks duration.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Health diet
Description: A Control group receiving health education about healthy diet. At the end of the 12 wk. period, the same measurements are repeated
Study: NCT06637930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Edentulous Alveolar Ridge In Mandible
Description: implant retained mandibular overdenture using telescopic attachment system. all the patients received 2 implants at the canine region bilaterally using sterelithographic guide , then healing period for 3 months for proper osseointegration , then digital intraoral scanning was performed to detect implant position using scannable bodies , abutments which act as primary crowns were designed on cad software then milled using premilled titanium abutments.the study grouping was performed then virtual model was done for the designing of the frameworks then milled according to the grouping of the study. Try in of the frameworks was done and overdentures were inserted.~* Retention force test was done using digital force gauge.~* Probing depth using Teflon coated periodontal probe.~* Marginal bone level and bone density were measured using digital periapical x-ray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Edentulous Alveolar Ridge In Mandible
Description: implant retained mandibular overdenture using telescopic attachment system. all the patients received 2 implants at the canine region bilaterally using sterelithographic guide , then healing period for 3 months for proper osseointegration , then digital intraoral scanning was performed to detect implant position using scannable bodies , abutments which act as primary crowns were designed on cad software then milled using premilled titanium abutments.the study grouping was performed then virtual model was done for the designing of the frameworks then milled according to the grouping of the study. Try in of the frameworks was done and overdentures were inserted.~* Retention force test was done using digital force gauge.~* Probing depth using Teflon coated periodontal probe.~* Marginal bone level and bone density were measured using digital periapical x-ray
Study: NCT06640738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arm 2
Description: This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arm 1
Description: This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun.
Study: NCT06640140

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised aerobic plus strength training
Description: Supervised moderate to high-intensity interval aerobic training plus moderate to high-intensity strength training.
Study: NCT05730335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Acoustic Pulse
Description: Transdermal Rapid Acoustic Pulse Treatments
Study: NCT06642415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery under loupes
Description: surgery performed under loupes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery under loupes
Description: surgery performed under loupes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery performed under microscope
Description: surgery performed under microscope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery performed under microscope
Description: surgery performed under microscope
Study: NCT06257485

Intervention type: DIAGNOSTIC_TEST
Intervention: 99mTc-pyrophosphate Single Photon Emission Computed Tomography
Description: All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram
Study: NCT05593289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: Physical activity that is planned, structured with repeated muscle movements with the aim of relearning motor skills, resistance of neck muscles and postural correction.
Study: NCT06312930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial pulse stimulation
Description: A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial pulse stimulation
Description: A single session of TPS will be performed, applying 1000 pulses in the session (single ultrashort (3 μs) ultrasound pulses, 0.2-0.25 mJ mm-2, \~5 Hz pulse frequency)
Study: NCT05338307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R-1,3-Butanediol
Description: Study participants will be taking 35mL of HVMN Ketone-IQ by mouth three times daily, with each dose containing 10 grams of R-1,3-Butanediol.
Study: NCT04995341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational ultracompact OCT and OCTA system
Description: Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece
Study: NCT06158958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-303
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-303
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion
Study: NCT05639699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motivational interview
Description: Quitting smoking with motivational interviewing
Study: NCT04995341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational ultracompact OCT and OCTA system
Description: Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational ultracompact OCT and OCTA system
Description: Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational ultracompact OCT and OCTA system
Description: Handheld bedside retinal OCT and OCT angiography imaging with an investigational portable system with ultracompact handpiece